メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
藤田医科大学でコンテンツを検索
ホーム
プロファイル
研究部門
研究成果
Scopus著者プロファイル
廣岡 芳樹
医学部・消化器内科学・第1
h-index
13462
被引用数
59
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1990 …
2026
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(534)
類似のプロファイル
(11)
フィンガープリント
Yoshiki Hirookaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Endoscopic Ultrasound
100%
Neoplasm
66%
Echography
56%
Diagnosis
33%
Pancreas Cancer
31%
Pancreas Disease
28%
Pancreatic Duct
27%
Autoimmune Pancreatitis
27%
Capsule Endoscopy
25%
Chronic Pancreatitis
21%
Double-Balloon Enteroscopy
21%
Elastography
20%
Disease
20%
Hepatocellular Carcinoma
19%
Intraductal Papillary Mucinous Tumor
19%
Malignant Neoplasm
17%
Adenoma
17%
Stomach Cancer
15%
Fine-Needle Aspiration
14%
Bile Duct
14%
Endoscopic Ultrasound Guided Fine Needle Biopsy
14%
Surgery
14%
Crohn's Disease
13%
Differential Diagnosis
13%
Colon
13%
Diagnostic Accuracy
13%
Shear Wave Elastography
12%
Stenosis
12%
Polyp
12%
Cancer
11%
Endoscopic Retrograde Cholangiopancreatography
11%
Endoscopic Submucosal Dissection
11%
Mucin
11%
Endoscopy
11%
Endoscopic Papillotomy
11%
Ultrasound Elastography
11%
Bevacizumab
11%
Atezolizumab
11%
Narrow Band Imaging
10%
Bleeding
10%
Overall Survival
10%
Adenocarcinoma
10%
Neuroendocrine Tumor
10%
Contrast-Enhanced Ultrasound
10%
Cholangiocarcinoma
10%
Esophagus
10%
Biopsy
10%
Gastrointestinal Stromal Tumor
9%
Cholestasis
9%
Angiography
9%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
39%
Pancreas Cancer
19%
Bevacizumab
19%
Atezolizumab
19%
Combination Therapy
16%
Neoplasm
15%
Hepatitis B Virus
15%
Disease
15%
Hepatitis C Virus
13%
Chronic Hepatitis C
11%
Crohn's Disease
11%
Interferon
11%
Ribavirin
10%
Malignant Neoplasm
10%
Acute Hepatitis B
9%
Gemcitabine
9%
Diseases
9%
Autoimmune Pancreatitis
8%
Sorafenib
8%
Stomach Cancer
8%
Lamivudine
8%
Bleeding
8%
Retrospective Study
8%
Chemotherapy
8%
Asunaprevir
7%
Daclatasvir
7%
Overall Survival
7%
Prevalence
7%
Chronic Hepatitis B
7%
Adverse Event
7%
Gastrointestinal Hemorrhage
6%
Prospective Study
6%
Peginterferon
6%
Hepatitis C Virus Subtype 1b
6%
Pancreas Adenocarcinoma
6%
Alpha Fetoprotein
6%
Intraductal Papillary Mucinous Tumor
6%
Polyp
6%
Lenvatinib
6%
Progression Free Survival
6%
Intestine Flora
5%
Antiviral Therapy
5%
Remission
5%
Epileptic Absence
5%
Bilirubin
5%
Peginterferon Alpha2b
5%
Keyphrases
Endoscopic Ultrasonography
14%
Pancreas
11%
Intraductal Papillary mucinous Neoplasm
11%
Atezolizumab Plus Bevacizumab
10%
Advanced Hepatocellular Carcinoma
10%
Combination Therapy
10%
Sustained Virological Response
9%
Endoscopic Ultrasound
9%
Hepatitis C Virus
9%
Pancreatic Cancer
8%
IgG4-related Sclerosing Cholangitis
8%
Intraductal Ultrasonography
8%
Japan
7%
Autoimmune Pancreatitis
7%
Hepatitis C Virus Genotypes
7%
Ribavirin
6%
Differential Diagnosis
6%
Interferon Sensitivity-determining Region
6%
Intraductal Ultrasound
6%
Elastography
6%
Mucin-producing Tumor
6%
Lenvatinib
6%
Main Pancreatic Duct
5%
Pancreatic Diseases
5%
Clinical Outcomes
5%
Chronic Pancreatitis
5%
Esophagus
5%
Pegylated Interferon alfa-2a
5%